BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling

European Journal of Cancer

Volumn 50, Issue 13, 2014, Pages 2251-2262

  Liu, Xiaoran ^a   Tian, Xiaodong ^a   Wang, Feng ^a   Ma, Yongsu ^a   Kornmann, Marko ^b   Yang, Yinmo ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Akt phosphorylation; BRG1; Chemoresistance; Gemcitabine; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CADHERIN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DEOXYCYTIDINE; DNA HELICASE; GEMCITABINE; NUCLEAR PROTEIN; PROTEIN KINASE B; SMARCA4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; CELL GROWTH; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOUSE; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CADHERINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEOXYCYTIDINE; DNA HELICASES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905114849     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.05.017     Document Type: Article

References (26)

1. R. Siegel, C. Desantis, and A. Jemal Colorectal cancer statistics, 2014 CA Cancer J Clin 64 2014 104 117
2. A. Vincent, J. Herman, R. Schulick, R.H. Hruban, and M. Goggins Pancreatic cancer Lancet 378 2011 607 620
3. H.A. Burris 3rd, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, and M.R. Modiano et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
4. Z. Wang, Y. Li, A. Ahmad, S. Banerjee, A.S. Azmi, and D. Kong et al. Pancreatic cancer: understanding and overcoming chemoresistance Nat Rev Gastroenterol Hepatol 8 2011 27 33
5. B.G. Wilson, and C.W. Roberts SWI/SNF nucleosome remodelers and cancer Nat Rev Cancer 11 2011 481 492
6. J.I. Wu Diverse functions of ATP-dependent chromatin remodeling complexes in development and cancer Acta Biochim Biophys Sin 44 2012 54 69
7. M. Dal Molin, S.M. Hong, S. Hebbar, R. Sharma, F. Scrimieri, and R.F. de Wilde et al. Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas Hum Pathol 43 2012 585 591
8. M. Numata, S. Morinaga, T. Watanabe, H. Tamagawa, N. Yamamoto, and M. Shiozawa et al. The clinical significance of SWI/SNF complex in pancreatic cancer Int J Oncol 42 2013 403 410
9. G. von Figura, A. Fukuda, N. Roy, M.E. Liku, J.P. Morris IV, and G.E. Kim et al. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma Nat Cell Biol 16 2014 255 267
10. T. Abbas, and A. Dutta P21 in cancer: intricate networks and multiple activities Nat Rev Cancer 9 2009 400 414
11. M. Watanabe, S. Sheriff, K.B. Lewis, S.L. Tinch, J. Cho, and A. Balasubramaniam et al. HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines Cancer Lett 315 2012 18 27
12. D.N. Reisman, J. Sciarrotta, W. Wang, W.K. Funkhouser, and B.E. Weissman Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis Cancer Res 63 2003 560 566
13. A. Sun, O. Tawfik, B. Gayed, J.B. Thrasher, S. Hoestje, and C. Li et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers Prostate 67 2007 203 213
14. M.F. Decristofaro, B.L. Betz, C.J. Rorie, D.N. Reisman, W. Wang, and B.E. Weissman Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies J Cell Physiol 186 2001 136 145
15. D.W. Parsons, M. Li, X. Zhang, S. Jones, R.J. Leary, and J.C. Lin et al. The genetic landscape of the childhood cancer medulloblastoma Science 331 2011 435 439
16. J. Bai, P. Mei, C. Zhang, F. Chen, C. Li, and Z. Pan et al. BRG1 is a prognostic marker and potential therapeutic target in human breast cancer PLoS ONE 8 2013 e59772
17. K. Sentani, N. Oue, H. Kondo, K. Kuraoka, J. Motoshita, and R. Ito et al. Increased expression but not genetic alteration of BRG1, a component of the SWI/SNF complex, is associated with the advanced stage of human gastric carcinomas Pathobiology 69 2001 315 320
18. G.B. Rosson, C. Bartlett, W. Reed, and B.E. Weissman BRG1 loss in MiaPaCa2 cells induces an altered cellular morphology and disruption in the organization of the actin cytoskeleton J Cell Physiol 205 2005 286 294
19. A.H. Shain, C.P. Giacomini, K. Matsukuma, C.A. Karikari, M.D. Bashyam, and M. Hidalgo et al. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer PNAS USA 109 2012 E252 E259
20. S. Kagawa, S. Takano, H. Yoshitomi, F. Kimura, M. Satoh, and H. Shimizu et al. Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells J Surg Res 178 2012 758 767
21. R. Koster, A. di Pietro, H. Timmer-Bosscha, J.H. Gibcus, A. van den Berg, and A.J. Suurmeijer et al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer J Clin Investig 120 2010 3594 3605
22. X. Xia, Q. Ma, X. Li, T. Ji, P. Chen, and H. Xu et al. Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer BMC Cancer 11 2011 399
23. A. Singh, and J. Settleman EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer Oncogene 29 2010 4741 4751
24. S. Lim, A. Becker, A. Zimmer, J. Lu, R. Buettner, and J. Kirfel SNAI1-mediated epithelial-mesenchymal transition confers chemoresistance and cellular plasticity by regulating genes involved in cell death and stem cell maintenance PLoS ONE 8 2013 e66558
25. E. Sánchez-Tilló, A. Lázaro, R. Torrent, M. Cuatrecasas, E.C. Vaquero, and A. Castells et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1 Oncogene 29 2010 3490 3500
26. T.D. Way, J.T. Huang, C.H. Chou, C.H. Huang, M.H. Yang, and C.T. Ho Emodin represses TWIST1-induced epithelial-mesenchymal transitions in head and neck squamous cell carcinoma cells by inhibiting the β-catenin and Akt pathways Eur J Cancer 50 2014 366 378